Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients

NCT: NCT07633535 · COMPLETED

NCT IDNCT07633535
StatusCOMPLETED
Start Date2022-10-01
Completion2023-04-30
SponsorGaziantep City Hospital (OTHER)
First posted
Last updated

Brief Summary

This single-center, observational study evaluated the LVAD index, defined as device-estimated pump flow divided by body surface area, in adult patients supported with continuous-flow left ventricular assist devices. The study included 34 patients with end-stage heart failure who had either an HVAD or HeartMate 3 device and were followed for six months. The study assessed the relationship between LVAD index and selected routine biochemical markers related to hepatic and renal status, including ALT, AST, LDH, BUN, and creatinine. The study also evaluated whether LVAD index was associated with rehospitalization during follow-up.

Frequently Asked Questions

What is LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients?

LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients is a clinical trial registered under NCT07633535. Current status: COMPLETED.

What is the status of NCT07633535?

The current status of NCT07633535 (LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients) is: COMPLETED.

When did LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients start?

LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients started on 2022-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.